-18 and IL-18 receptor levels were measured and the activity of exogenous IL-18 on HIV-negative and HIV-positive PBMC was evaluated in terms of Vc9Vd2 T-cell proliferation, memory subsets, cytokine expression and CD107a expression. Interleukin-18 stimulation increased proliferation, enhanced the accumulation of effector memory cells, and increased expression of cytotoxic markers in HIV-negative controls. When Vc9Vd2 T cells from HIV-positive individuals were stimulated with isopentenyl pyrophosphate in the presence of IL-18, there was increased proliferation, accumulation of memory cells, and higher expression of CD56, NKG2D and CD107a (markers of cytotoxic effector phenotype). Interleukin-18 stimulation specifically expanded the Vc9-JcP + subset of Vc9Vd2 T cells, as was expected for normal responses to phosphoantigen. Interleukin-18 is a potent stimulator of Vc9Vd2 T-cell proliferation and effector function. Therapies directed at reconstituting Vc9Vd2 T-cell activity in HIV-positive individuals should include stimulators of IL-18 or direct cytokine supplementation.
Summary
The study aimed to identify an immunoregulatory factor that restores the phosphoantigen response of Vc9Vd2 + T cells from HIV-positive individuals on antiretroviral therapy. It was designed to characterize the effects of interleukin-18 (IL-18) on proliferation and effector function in Vc9Vd2 T cells from HIV-negative individuals and test whether exogenous IL-18 reconstitutes the Vc9Vd2 T-cell response to phosphoantigen from HIVpositive donors. Vc9Vd2 T cells from HIV-negative individuals responded strongly to phosphoantigen or aminobisphosphonate stimulation of peripheral blood mononuclear cells (PBMC), whereas cells with similar T-cell receptor profiles from HIV-positive individuals only responded to aminobisphosphonate. Interleukin-18 was higher after aminobisphosphonate stimulation due to activation of the inflammasome pathway. Both IL-18 and IL-18 receptor levels were measured and the activity of exogenous IL-18 on HIV-negative and HIV-positive PBMC was evaluated in terms of Vc9Vd2 T-cell proliferation, memory subsets, cytokine expression and CD107a expression. Interleukin-18 stimulation increased proliferation, enhanced the accumulation of effector memory cells, and increased expression of cytotoxic markers in HIV-negative controls. When Vc9Vd2 T cells from HIV-positive individuals were stimulated with isopentenyl pyrophosphate in the presence of IL-18, there was increased proliferation, accumulation of memory cells, and higher expression of CD56, NKG2D and CD107a (markers of cytotoxic effector phenotype). Interleukin-18 stimulation specifically expanded the Vc9-JcP + subset of
Introduction
The Vc9Vd2 T-cell receptor (TCR) is required for cellular responses to five carbon pyrophosphate intermediates (phosphoantigens) in the pathway for cholesterol biosynthesis. 1, 2 Responses to these phosphoantigens are MHC-unrestricted and specific to a subset of cells expressing the Vc9-JcP rearrangement. 3, 4 Because isopentenyl pyrophosphate (IPP) and other stimulatory phosphoantigens are ubiquitous, a constant positive selection 
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amplifies the Vc9-JcPVd2 + subset in blood and lymphoid tissues. 5 Hence, a majority of circulating Vc9Vd2 T cells in humans have central or effector memory phenotypes due to chronic phosphoantigen exposure and are potently cytotoxic against many tumours and microbially infected cells. [6] [7] [8] [9] Phosphoantigen-responsive Vc9-JcPVd2 + T cells usually comprise > 75% of circulating cd T cells in HIVnegative (HIV-) adults, and this population responds so rapidly to cancer or infected cells that it resembles innate immunity. 10, 11 Self/non-self discrimination by Vc9-JcPVd2 + T cells depends mainly on natural killer (NK) or killer inhibitor receptors. [12] [13] [14] [15] Immunoglobulin binding to cell surface FcgRIII also increases Vc9-JcPVd2 + T-cell cytotoxicity. 16, 17 In addition to direct effector activities, these cd T cells also co-stimulate NK cells for increased tumour cell or dendritic cell killing. 18, 19 Rapid loss of Vc9-JcPVd2 T cells is an important part of acquired immunodeficiency disease and is among the earliest T-cell defects after HIV infection. [18] [19] [20] [21] [22] [23] [24] Among all persons with HIV disease only natural virus suppressors (also termed elite controllers) maintain near normal Vc9Vd2 levels and the frequencies of CD27 -CD45RA
effector cells are similar to those found in HIV-control donors. [25] [26] [27] Reconstitution of the Vc9Vd2 TCR repertoire occurs after prolonged antiretroviral therapy but these cells remain unresponsive to phosphoantigen stimulation and cannot be amplified in vitro despite having TCR sequences capable of responding to IPP. [28] [29] [30] Curiously, these reconstituted cells are responsive to stimulation with aminobisphosphonate drugs including zoledronic acid (ZOL) that increase intracellular IPP in antigen-presenting cells (APC). 30, 31 The mechanism of action for aminobisphosphonate (ZOL) drugs is competitive inhibition of farnesyl diphosphate synthase, which prevents conversion of IPP into downstream farnesyl diphosphate synthase and geranylgeranyl pyrophosphate (GGPP). ZOL is incorporated into APC cells where it increases intracellular IPP, which is presented to Vc9-JcPVd2 T cells by cell surface butyrophilin3A1. [31] [32] [33] [34] GGPP is an important negative regulator of the NOD-like receptor pyrin containing 3 (NLRP3) inflammasome and farnesyl diphosphate synthase inhibitors including ZOL reduce GGPP levels. Consequently, ZOL indirectly activates NLRP3 and increases IPP; these effects are sufficient to stimulate Vc9Vd2 T-cell proliferation, differentiation and effector function.
We postulated that the differences in IPP versus ZOL responses among HIV-positive (HIV+) individuals might be explained by activity of the NLRP3 inflammasome including release of interleukin-18 (IL-18) and/or IL1b. [33] [34] [35] [36] Insufficient production of IL-18 and/or IL-1b in peripheral blood mononuclear cells (PBMC) from HIV+ patients might explain the failed response to IPP. 37 Here, we assessed the effects of IL-18 on Vc9Vd2 T-cell stimulation and tested whether this cytokine could reconstitute the IPP response in PBMC from HIV+ individuals.
Materials and methods

Samples
Venous blood samples were obtained from HIV+ and HIV-individuals. PBMC were purified by Ficoll gradient centrifugation and stored as viable, frozen cells. All HIV+ individuals were being treated with combination antiretroviral therapy and all were suppressed to < 50 copies/ml of plasma viral RNA at the time blood specimens were obtained. Informed written consent was obtained from all patients and this study was approved by the Institutional Review Board of the University of Maryland, Baltimore (Baltimore, MD).
Cell culture
Purified PBMC were re-suspended in R-10 medium consisting of RPMI-1640 supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY), 2 mmol/l L-glutamine (Invitrogen, Camarillo, CA), 1 U/ml penicillin/ streptomycin (Invitrogen) and 100 U/ml recombinant human IL-2 (Tecin, Biological Resources Branch, NIH, Bethesda, MD). Zoledronic acid at a concentration of 1 lM (zoledronate/Zol; Sigma, St Louis, MO) or IPP (Sigma) at a concentration of 15 lM was added to trigger Vc9Vd2 + cell proliferation. Cultures were incubated at 37°in 5% CO 2 and replenished every 3 days by adding R-10 medium containing 100 U/ml IL-2 as needed. On day 14, cells were rested by shifting to medium with lower IL-2 (10 U/ml) for 2 days. Phenotyping and functional assays were performed on ex vivo PBMCs or cells harvested 14-16 days after stimulation. An absolute Vc9Vd2 T-cell count on day 14 was calculated as: frequency of Vc9Vd2 T cells in culture * (specific cells/ll). Interleukin-18 inhibition in PBMC cultures was measured with additional compounds GGPP (Sigma) at a concentration of 15 lM, 15D (A438079 HCl; R&D Systems, Minneapolis, MN) at a concentration of 100 lM, and Caspase-1 (Ac-YVAD-cmk; Invivogen, San Diego, CA) at a concentration of 50 lM. CytoPerm for 20 min at 4°. Samples were read on a BD Accuri C6 Flow Cytometer. Data were analysed by FLOWJO (TreeStar, San Jose, CA) and GRAPHPAD PRISM (GraphPad Software, La Jolla, CA).
Granule mobilization assay
Day 16 (rested) cells were collected and re-suspended at 1 9 10 6 cells/ml in fresh R-10 medium and re-stimulated with 15 lM IPP. Cells were plated with anti-CD107a-phycoerythrin-Cy7, Brefeldin A (1 : 1000; BD Biosciences, San Jose, CA), and Monensin (1 : 1500; BD Biosciences). After 6 hr of incubation at 37°, cells were washed with cold PBS and stained for surface marker using antiVd2-FITC, followed by fixation/permeabilization (BD Biosciences), and intracellular staining with anti-Perforinphycoerythrin and anti-CCL5-Alexafluor647 (Biolegend).
Antigen re-stimulation
Day 16 (rested) cells were re-suspended at 1 9 10 6 cells/ ml in fresh R-10 medium and re-stimulated with 15 lM IPP (Sigma). After 24 hr of incubation at 37°, cells were pelleted and supernatants were collected. Cell-free interferon-c (IFN-c) levels were determined by ELISA. Polystyrene plates (Nunc MaxiSorp; Thermo Fisher, Waltham, MA) were coated with capture antibody in PBS overnight at 25°. The plates were washed with 50 mM Tris-HCl, 0Á2% Tween-20, and then blocked for 90 min at 25°with assay buffer, PBS containing 4% BSA (Sigma). Then 50 ll of sample or standard prepared in assay buffer and incubated at 37°for 2 hr. The plates were washed and 100 ll of biotinylated detecting antibody in assay buffer was added and incubated for 1 hr at 25°. After washing, strepavidin-peroxidase polymer in casein buffer (RDI, Flanders, NJ) was added and incubated at 25°for 30 min. The plate was washed and 100 ll of commercially prepared substrate (TMB Dako, Agilent Technologies, Santa Clara, CA) was added and incubated at 25°f or approximately 10-30 min. The reaction was stopped with 100 ll 2 M HCl and the absorbance at 450 nm (A 450 ) (minus A 650 ) was read on a microplate reader (Molecular Dynamics, GE Healthcare, Uppsala, Sweden). A curve was fitted to the standards using a computer program (SOFTPRO; Molecular Dynamics) and cytokine concentration in each sample was calculated from the standard curve equation.
RNA extraction, RT-PCR, PCR
RNA extraction, reverse transcription, and PCRs were performed as previously described using the following primers for Vc9 chain: oligo-Vc9 (5 0 -ATC AAC GCT GGC AGT CC-3 0 ) and oligo-Cy-1 (5 0 -GTT GCT CTT CTT TTC TTG CC-3 0 ). 38 
Cloning and sequencing
Cloning and sequencing reactions were performed as previously described. 39 In summary, Vc9 coding region PCR products were purified by gel extraction. Purified PCR products were denatured and ligated into the plasmid vector. Ligated vectors were transfected into bacterial colonies and grown overnight. Colonies containing recombinant Vc9 chain plasmids were amplified in bacterial suspensions. Suspensions were processed and used as DNA templates for amplifying individual Vc9 chain sequences. PCR was performed using M13 forward primer (5 0 -GTA AAA CGA CGG CCA G-3 0 ) and reverse M13 primer (5 0 -CAG GAA ACA GCT ATG AC-3 0 ). PCR products were purified by size exclusion. Sequencing reactions were performed using M13 Forward or M13 Reverse primers for each target. Sequences were loaded on an automated sequencer and analysed using SEQUENCHER (Gene Codes Corp, Ann Arbor, MI) and MACCLADE (Sinauer Associates, Sunderland, MA) software.
Statistical analysis
Statistical analyses were performed using the software GRAPHPAD PRISM. For each measured variable, a D'Agostino and Pearson omnibus normality test (GraphPad Software, La Jolla, CA) was performed to determine if values were normally distributed. Values that were not normally distributed were excluded from further statistical analyses. Differences between normally distributed means were evaluated using a Student's t-test when comparing two groups.
Results
Inhibiting IL-18 in PBMC cultures
Zoledronic acid inhibits GGPP production and indirectly stimulates the inflammasome. 35 We confirmed that ZOL treatment increased the production of NLRP3 products IL-18 and IL-1b via a Caspase-1-induced mechanism. Ex vivo PBMC were stimulated for 24 hr with ZOL, IPP or control (no stimulus) in the presence of IL-2. Low levels of endogenous IL-18 (10 pg/ml) were detected in both control and IPP cultures even in the absence of ZOL. IL-18 levels increased to 20 pg/ml in the presence of ZOL after 24 hr (see Supplementary material, Fig. S1a) and were significantly higher than IL-18 levels in control or IPP-stimulated cultures. 15D, a P2X7 receptor antagonist that inhibits NLRP3 activity added with GGPP significantly reduced ZOL-stimulated IL-18 production but did not reduce cytokine to control levels. 36 The Caspase-1 inhibitor YVAD decreased ZOL-stimulated IL-18 production fourfold and decreased endogenous control IL-18 production twofold.
Since YVAD inhibits Caspase-1, which processes the precursor forms of both IL-18 and IL-1b, this inhibitor was not specific for IL-18. To test the role for IL-18 in Vc9Vd2 T-cell activation, we used blocking antibodies against the IL-18 receptor a chain or neutralized soluble IL-18 with a monoclonal antibody. A bioassay for IL-18, measuring IFN-c production in KG-1 cell cultures that were stimulated with exogenous IL-18, was used to evaluate IL-18 blocking reagents. A natural inhibitor of IL-18, IL-18-binding protein, was effective at reducing the IFN-c response in KG-1 cells. 40 A concentration of 0Á8 lg/ml IL-18-binding protein blocked > 95% of IL-18 stimulated IFN-c production in KG-1 cell cultures and was used here as an inhibitor of IL-18 in PBMC cultures (see Supplementary material, Fig. S1b ).
High level IL-18Ra expression on Vc9Vd2 T cells
After confirming that ZOL induces IL-18 production in PBMC, we next evaluated the distribution of IL-18 receptor on leucocyte subpopulations. We compared IL-18Ra levels on NK, CD4, CD8 T and Vc9Vd2 T cells. The IL-18Ra expression was highest on Vc9Vd2 T cells and was above the levels seen for NK or CD8 T cells (Fig. 1a) . This is important because both NK and CD8 T cells respond directly to IL-18. 40 The circulating Vc9Vd2 + T-cell population was highly skewed towards a central memory phenotype compared with ab CD4 or CD8 T cells and this might affect differences in IL-18R density.
Even accounting for differences in the proportion of central memory cells, Vc9Vd2 + T cells still had higher levels of IL-18Ra compared with both CD4 and CD8 T cells (Fig. 1b) . Next, we assessed the relationships between IL-18R levels and CD56 expression on NK and Vc9Vd2 T cells (Fig. 1c) . There was no apparent correlation between CD56 expression and IL-18R levels for Vc9Vd2 + T cells but IL-18Ra levels were significantly higher among CD56 . ****P < 0Á0001, **P < 0Á01, *P < 0Á05. + cells among all subsets that were tested (Fig. 1d) . In PBMC from HIV + donors there were insufficient numbers of Vc9Vd2 T cells to stratify on the basis of CD56 expression.
IL-18 enhances Vc9Vd2 T-cell proliferation
To examine the effects of IL-18 on Vc9Vd2 T-cell proliferation we treated PBMC with IPP in the presence or absence of IL-18. PBMC from 15 control (HIV-) donors were stimulated with ZOL or IPP (Fig. 2a) . As expected, proliferation responses to ZOL were higher than with IPP. Next, we added 10 or 50 ng/ml of IL-18 to PBMC that were stimulated with IPP. Adding the cytokine increased Vc9Vd2 + T-cell proliferation to levels comparable to ZOL stimulation (Fig. 2a) and the effect was blocked by adding IL-18-binding protein (Fig. 2b ). There were no significant differences between 10 and 50 ng/ml IL-18 doses.
We then tested whether IL-18 could restore proliferative responses to IPP in PBMC from eight HIV+ donors. Interleukin-18 supplementation increased the proliferative response to IPP in six out of eight HIV+ donors and even exceeded proliferation levels seen with ZOL treatment (Fig. 2c) /ml) were stimulated with 1 lM zoledronic acid (ZOL) or 15 lM isopentenyl pyrophosphate (IPP) on day 0 in R-10 medium supplemented with 100 U IL-2. Exogenous IL-18 (10 or 50 ng) was added on days 0, 1 and 2. Proliferation was assessed on day 14 by flow cytometry. Cells were stained for Vd2 and counted (n = 15 HIV-donors). (b) PBMC (1Á5 9 10 6 /ml) were stimulated with 1 lM ZOL or 15 lM IPP on day 0 in R-10 medium supplemented with 100 U IL-2. Exogenous IL-18 (10 ng/ml) or IL-18 bp (0Á8 lg/ml) was added on days 0, 1 and 2. Proliferation was assessed on day 14 by flow cytometry. Cells were stained for Vd2 and counted. n = 5 donors (c) PBMCs (2Á0 9 10 6 /ml) were stimulated with 1 lM ZOL or 15 lM IPP on day 0 in R-10 medium supplemented with 100 U IL-2. Exogenous IL-18 (10 ng or 50 ng) was added on days 0, 1 and 2. Proliferation was assessed on day 14 by flow cytometry. Cells were stained for Vd2 and counted. n = 8 donors. **P < 0Á01, *P < 0Á05. decreased the proportion of naive cells even further (Fig. 3a) .
Unexpectedly, IL-18 supplementation decreased the percentage and the levels of CD16 expression on Vc9Vd2 + cells (Fig. 3b) . The percentage of cells expressing NKG2D increased with IL-18 supplementation compared to IPP alone (Fig. 3c) . A small decrease in the percentage of CD56 + cells was observed after IL-18 treatment but the levels of CD56 expression remained unchanged (Fig. 3d) .
The percentage of DNAM-1 + cells increased as did the levels of DNAM-1 expression on Vc9Vd2 T cells exposed to IL-18. The proportion of DNAM-1 + Vc9Vd2 T cells exceeded 99% in the high dose IL-18 group (Fig. 3e) . MFI n = 12, DNAM-1 n = 13. ***P < 0Á001, **P < 0Á01, *P < 0Á05.
ª 2017 John Wiley & Sons Ltd, Immunology, 151, 385-394 (Fig. 4a) . However, this trend was not statistically significant due to donor variability within the IPP treatment group. There were no measurable changes in the proportion of central memory, terminally differentiated or naive Vc9Vd2 cells in the IL-18-treated group compared with IPP alone. IL-18 supplementation did not affect CD16 expression (Fig. 4b) but slightly increased NKG2D expression and the percentage of NKG2D + cells compared with treatment with IPP alone (Fig. 4c) . Interleukin-18 supplementation slightly increased the percentage of CD56 + cells and significantly raised CD56 expression compared with IPP alone (Fig. 4d) . The percentage of DNAM-1 + cells and DNAM-1 expression were slightly increased with IL-18 supplementation compared with IPP alone but these results were not significant (Fig. 4e) . Populations shown were gated on Vd2 + (n = 9) *P < 0Á05. 
Recall responses to IPP
One way to assess Vc9Vd2 + T-cell functional responses is to expand the Vc9Vd2 population from PBMC with ZOL or IPP treatment for 14 days, then rest with low IL-2 for 2 days before re-stimulating with IPP and measuring the short-term 'recall' response. Here, expanded cells (ZOL or IPP) were rested with low IL-2 (10 U/ml) for 2 days then re-stimulated with 15 lM IPP and no additional IL-2. CD107a degranulation, perforin expression and IFN-c secretion were measured as markers of effector responses. CD107a degranulation in conjunction with perforin expression was used as a surrogate marker for perforinmediated cytotoxicity because we did not have sufficient numbers of cells from all donors for direct cytotoxicity assays. In PBMC from HIV-negative donors, IL-18 supplementation yielded slightly higher percentages of CD107a + Perforin + Vc9Vd2 T cells compared with IPP without IL-18 (Fig. 5a ). Vc9Vd2 T cells secreted more IFN-c after IL-18 plus IPP compared with IPP alone (Fig. 5b) . In HIV+ donors, we saw similar, non-significant increases in CD107a + Perforin + Vc9Vd2 cells from the IL-18 treatment groups compared with the IPP only group (Fig. 5c) . However, there were no differences in IFN-c secretion between IL-18-supplemented and IPP alone groups (Fig. 5d) .
IL-18 addition does not skew the Vc9 chain repertoire
The TCR-c chain rearrangement Vc9-JcP is required for phosphoantigen responses. We tested whether IL-18 supplementation changed the proportion of Vc9-JcP + cells in PBMC from five HIV+ donors after IPP stimulation and proliferation. A sample of 100 Vc9 chains were sequenced from PBMC stimulated with IPP only or IPP plus IL-18 (10 ng/ml group). There were no differences in the frequencies of Vc9-JcP rearranged chains between the two groups (Fig. 5e) . We also measured the frequency of eight common public clonotypes (predicted from the nucleotype sequences) among all Vc9-JcP rearranged c chains. The frequencies of common public clonotypes were similar in IPP and IPP plus IL-18 treatment groups (Fig. 5f) . Hence, IL-18 supplementation increased the proliferative response to IPP but did not alter the proportion of Vc9-JcP rearrangements or select for a specific subset of public clonotypes.
Discussion
Depletion of Vc9-JcPVd2 T cells and decreased responses to phosphoantigens are hallmarks of HIV disease. [21] [22] [23] Only natural virus suppressors (also termed elite controllers) who are capable of controlling viraemia in the absence of antiretroviral therapy have normal Vc9Vd2
T-cell responses to phosphoantigen. 27 The absence of phosphoantigen responses even after long-term therapy, is difficult to explain as molecular analyses of the c-chain repertoire showed reconstitution of cells expressing Vc9-JcP rearranged chains and predicted a phosphoantigen response. [30] [31] [32] However, Vc9Vd2 T cells from HIV+ donors did respond to aminobisphosphonate stimulation suggesting that mechanisms other than TCR recognition of antigen might be responsible for the lack of responses in HIV+ donors. 32 Here, we identify IL-18 as a cytokine potentially capable of reversing the HIV-associated defect in phosphoantigen responses and show that aminobisphosphonate stimulation increased the cytokine levels.
The effects of IL-18 on Vc9Vd2 T cells included increased proliferative responses to phosphoantigen stimulation, a shift toward effector memory subsets, increased expression of CD56 that is associated with Vc9Vd2 cell cytotoxicity, and elevated expression of NK receptors that are important for Vc9Vd2 T-cell cytotoxic effector function. 41 These effects are over and above the impact of phosphoantigen alone.
It is important to note that IL-18 supplementation increased the proliferative response to phosphoantigen in PBMC from both control and HIV+ donors. This accounts for a consistent finding that aminobisphosphonate responses usually exceed phosphoantigen responses for most HIV-donors and emphasizes the importance of inflammasome activation for optimal Vc9Vd2 + T-cell responses. In PBMC from HIV+ donors, the response to phosphoantigen alone is low compared with control individuals, and the impact of IL-18 is immediately obvious. The proportion of memory Vc9Vd2 + T cells in HIV+ donors is also low because naive cells constitute a significantly greater proportion of total Vc9Vd2 + T cells due to poor phosphoantigen responses in vivo. 5 The apparent advantage of IL-18 for HIV+ donor PBMC reflects the ability of IL-18 to activate cells and increase the memory subset. Vc9Vd2 T cells with a CD27 À CD45RA -effector phenotype are depleted during active tuberculosis, progressing HIV infection, and tuberculosis/HIV coinfection. [42] [43] [44] Interleukin-18, or compounds such as aminobisphosphonates that increase IL-18 production might be therapeutic for these infections partly by reconstituting the Vc9Vd2 T-cell memory subsets.
Additionally, since Vc9Vd2 T cells provide co-stimulation for NK cells through 41BBL and ICOS, reconstitution of functional Vc9Vd2 cells would improve NK cell cytotoxicity against tumour cells and dendritic cells. 18, 19 Unfortunately, IL-18 supplementation decreased the proportion of CD16 + Vc9Vd2 T cells in both populations and might limit antibody-mediated cellular cytotoxicity effector function. 45 Interleukin-18 was seen to increase the proportion of NKG2D + Vc9Vd2 cells in PBMC from HIV+ and control donors that is important for enhancing direct cytotoxicity.
Based on our understanding of IL-18 effects on Vc9Vd2 T-cell proliferation, we can postulate that delivering this cytokine may be one part of a broader immunotherapeutic approach targeting Vc9Vd2 T cells in HIV+ individuals. Our studies on IL-18 do not fully explain the failure to reconstitute normal cell levels or phosphoantigen responses after prolonged antiretroviral therapy but hint at insufficient numbers of functional monocytic cells, insufficient inflammasome activation, or even suppression of the inflammasome as possible mechanisms responsible for the failure to reconstitute Vc9Vd2 T cells after prolonged antiretroviral therapy.
Knowing the importance of inflammasome activity for Vc9Vd2 + T-cell phosphoantigen responses encourages further studies of HIV+ individuals receiving aminobisphosphonate therapy for osteoporosis to learn whether inflammasome activation impacts the function of Vc9Vd2 + T cells and reconstitutes this important T-cell subset. 
